0
Skip to Content
Context Therapeutics
Who We Are
Our Technology
Pipeline
CTIM-76
CT-202
Patients
Careers
Investors & News
Context Therapeutics
Who We Are
Our Technology
Pipeline
CTIM-76
CT-202
Patients
Careers
Investors & News
Who We Are
Folder: Our Science
Back
Our Technology
Pipeline
CTIM-76
CT-202
Patients
Careers
Investors & News

Poster 2625 - Identification of CTX-30916 as a new antagonist of progesterone receptor signaling pathways

Poster
Apr 1
Written by Martin Lehr
Martin Lehr
Next
Next

Poster 926 - Onapristone enhances the anti-proliferative effects of CDK4/6 inhibitors in preclinical in-vitro breast cancer models

About Us
Leadership
Partnering
Contact Us

Our Technology
Pipeline
CTIM-76
CT-202

Patients
Clinical Trials
Expanded Access Policy
Investigator Led Trials

Investors & Media
News
Publications

Careers
Open Positions

Privacy Policy          Terms of Use

© Context Therapeutics Inc. 2026  |  All Rights Reserved